GlassScriptPhysician profile
Sara A Lohser
NPI 1942468582
$4,134.88
in general payments reported to CMS, 2019-2025
37 companies · $689 in 2025
The $689 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $942 · 2020: $198 · 2021: $387 · 2022: $687 · 2023: $593 · 2024: $639 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,846 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,846.30 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $640.42 | 2019-2025 | |
| Galderma Laboratories, L.P. | $392.09 | 2019-2025 | Nemluvio |
| Ucb, INC. | $317.00 | 2021-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $291.87 | 2019-2025 | Winlevi, Blu-U, Odomzo |
| Janssen Biotech, INC. | $268.79 | 2019-2025 | Tremfya, Remicade, Simponi |
| Novartis Pharmaceuticals Corporation | $248.74 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $217.38 | 2019-2024 | Dupixent |
| Lilly USA, LLC | $215.56 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Allergan, INC. | $209.79 | 2021-2022 | |
| Amgen INC. | $184.20 | 2020-2025 | Otezla, Otezla |
| Biofrontera INC. | $117.93 | 2022-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.48 | 2022-2024 | Spevigo, Cyltezo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $85.00 | 2019-2025 | Cabtreo, Siliq, Jublia |
| Leo Pharma INC. | $80.04 | 2019-2022 | |
| Genzyme Corporation | $79.69 | 2019-2023 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $65.11 | 2022-2025 | Sotyktu |
| Organogenesis INC. | $59.99 | 2023 | Puraply |
| Smith+Nephew, INC. | $59.82 | 2024 | Stravix, Grafix Pl |
| Pfizer INC. | $56.82 | 2021-2025 | |
| Revance Therapeutics, INC. | $51.66 | 2025 | Daxxify |
| Incyte Corporation | $41.84 | 2022-2025 | Opzelura |
| Almirall LLC | $38.11 | 2019-2022 | |
| Journey Medical Corporation | $35.18 | 2022 | |
| Biocon Biologics INC | $32.40 | 2025 | Yesintek |
| Genentech USA, INC. | $30.78 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $24.45 | 2022 | |
| Kyowa Kirin, INC. | $21.14 | 2024 | Poteligeo |
| Prugen, INC. Pharmaceuticals | $21.05 | 2019 | |
| Aclaris Therapeutics, INC. | $20.54 | 2019 | |
| Dermira, INC. | $19.34 | 2019 | |
| Arcutis Biotherapeutics, INC. | $18.01 | 2023 | |
| Epi Health, LLC | $17.81 | 2021 | |
| Polynovo North America LLC | $16.67 | 2023 | |
| Conmed Corporation | $14.65 | 2023 | Visiclear |
| Dermavant Sciences, INC. | $14.58 | 2023 | Vtama |
| Vyne Pharmaceuticals INC. | $13.11 | 2020 | |
| Kerecis Limited | $8.84 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Lohser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.